期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

PET-CT在卵巢癌中的临床应用价值 被引量：7

The application of PET-CT in ovarian cancer
下载PDF
导出
摘要 卵巢癌是妇科较常见的恶性肿瘤及致死原因,正电子发射体层显像(PET)对于卵巢癌的诊断、分期、复发及疗效监测及预后方面优于常规的检测手段(CT、MRI及肿瘤标志物检查);PET-CT对指导手术有重要价值;特异性PET显像剂的研制已取得初步成果,124I-C6.5diabody已经成功用于动物的PET-CT。 Ovarian cancer is the leading cause of death among women with gynecologic malignancies, ^18Ffluorodeoxyglucose （^18SF-FDG ） positron emission tomography （ PET ） is a well-established method for detecting, staging, cancer recurrence and therapeutic response and prognosis of ovarian cancer. PET-CT is helpful for the surgry guide and second-look laparotomy. Specific radiolabel pharmacies to ovarian cancer such as ^124I-C6.5 aliabody has been successfully imaged in animal with PET-CT.
作者 董孟杰 林祥通 赵军
机构地区 复旦大学附属华山医院核医学科
出处 《国外医学（放射医学核医学分册）》 2005年第5期209-213,共5页 Foreign Medical Sciences(Section of Radiation Medicine and Nuclear Medicine)
关键词 卵巢癌 正电子发射体层显像 计算机体层成像 18F-氟代脱氧葡萄糖 ovarian carcinoma positron emission tomography computed tomography ^18F-fluorodeoxyglucose
分类号 R737.31 [医药卫生—肿瘤]
  • 相关文献

参考文献19

  • 1Kurokawa T, Yoshida Y, Kawahara K, et al. Expression of GLUT-1glucose transfer, cellular proliferation activity and grade of tumor correlate with [F-18]-fiuorodeoxyglucose uptake by positron emission tomography in epithelial tumors of the ovary[J]. Int J Cancer,2004, 109(6): 926-932.
  • 2Torizuka T, Kanno T, Futatsubashi M, et al. Imaging of gynecologic tumors: comparison of (11)C-choline PET with (18)F-FDG PET[J].J Nucl Med,2003, 44(7): 1051-1056.
  • 3Robinson MK, Doss M, Shaller C, et al. Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine- 124 labeled anti-HER2 diabody[J]. Cancer Res, 2005,65(4): 1471-1478.
  • 4Nishizawa S, Inubushi M, Okada H. Physiological 18F-FDG uptake in the ovaries and uterus of healthy female volunteers[J]. Eur J Nucl Med Mol Imaging, 2005, 32(5): 549-556.
  • 5Torizuka T, Nobezawa S, Kanno T, et al. Ovarian cancer recurrence: role of whole-body positron emission tomography using2[fluorine-18]-fluoro-2-deoxy-D-glucose[J]. Eur J Nucl Med Mol Imaging, 2002, 29(6): 797-803.
  • 6Nakamoto Y, Saga T, Ishimori I, et al. Clinical value of positron emission tomography with FDG for recurrent ovarian cancer[J]. Am J Roentgenol, 2001, 176(6): 1449-1454.
  • 7Menzel C, Dobert N, Hamscho N, et al. The influence of CA 125and CEA levels on the results of (18)F-deoxyglucose positron emission tomography in suspected recurrence of epithelial ovarian cancer[J]. Strahlenther Onkol, 2004, 180(8): 497-501.
  • 8Havrilesky LJ, Kulasingam SL, Matchar DB, et al. FDG-PET for management of cervical and ovarian cancer[J]. Gynecol Oncol,2005, 97(1): 183-191.
  • 9Kim EE. Whole-body positron emission tomography and positron emission tomography/computed tomography in gynecologic oncology[J]. Int J Gynecol Cancer, 2004, 14(1): 12-22.
  • 10Unger JB, Ivy JJ, Connor P, et al. Detection of recurrent cervical cancer by whole-body FDG PET scan in asymptomatic and symptomatic women[J]. Gynecol Oncol, 2004, 94(1): 212-216.

同被引文献69

  • 1尚慧玲,李光仪,王刚,林铁成.子宫内膜癌术前MRI及PET的诊断价值[J].中国妇产科临床杂志,2004,5(4):271-272. 被引量：5
  • 2赵军,林祥通.关于PET/CT临床应用的若干问题[J].中华核医学杂志,2005,25(2):69-71. 被引量：17
  • 3赵军,管一晖,左传涛,华逢春,林祥通.^(18)F-FDG PET/CT在探测卵巢癌术后复发和转移中的价值[J].中国肿瘤,2007,16(3):187-189. 被引量：15
  • 4Omura GA, Brady MF, Homesley HD, et al. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience[J].J Clin Oncol,1991, 9 (7):1138-1150.
  • 5Murakami M, Miyamoto T, Iida T et al. Whole-body positron emission tomography and tumor marker CA125 for detection of recurrence in epithelial ovarian cancer[J].Int J Gynecol Cancer, 2006, 16 (Suppl 1): 99-107.
  • 6Dong MJ, Zhao K, Lin XT, et al. Role of fluorodeoxyglucose-PET versus fluorodeoxyglucose-PET/computed tomography in detection of unknown primary tumor: a meta-analysis of the literature[J].Nucl Med Commun, 2008, 29 (9): 791-802.
  • 7Huebner RH, Park KC, Shepherd JE, et al. A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer[J].J Nucl Med,2000, 41 (7): 1177-1189.
  • 8Bristow RE, del Carmen MG, Pannu HK, et al. Clinically occult recurrent ovarian cancer: patient selection for secondary cytoreductive surgery using combined PET/CT[J].Gynecologic Oncology, 2003,90 (3): 519-528.
  • 9Pannu HK, Cohade C,Bristow RE,et al. PET-CT detection of abdominal recurrence of ovarian cancer: radiologic-surgical correlation[J].Abdom Imaging, 2004, 39(3): 398-403.
  • 10Bristow RE, Giuntoli RL 2nd, Pannu HK, et al. Combined PET/CT for detecting recurrent ovarian cancer limited to retroperitoneal lymph nodes[J].Gynecologic Oncology, 2005,99 (2): 294-300.

引证文献7

二级引证文献33

国外医学（放射医学核医学分册）
2005年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部